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ABSTRACT
Introduction: The occurrence of atypical femur
fractures (AFFs) in patients on prolonged
bisphosphonate treatment has been gaining
medical attention, but the use of
pharmacotherapy for these fractures has not
been explored in detail. The authors describe a
case of AFFs successfully treated with once-weekly
administration of 56.5 lg teriparatide (TPTD).
Case Presentation: The patient was a 74-year-
old female patient who had been taking
alendronate for approximately 6 years and
who suffered with a fall while walking. X-rays
revealed a subtrochanteric right femur fracture.
The contralateral femur showed cortical
thickening and a transverse radiolucent
fracture line. Based on these specific features,
the patient was diagnosed with AFF. The patient
underwent osteosynthesis with intramedullary
nailing for the right fracture. Alendronate
treatment was discontinued. Low-intensity
pulsed ultrasonography therapy did not affect
the healing of the fracture with delayed union,
even after 3 months of application.
Prophylactic osteosynthesis was performed for
the subtrochanteric left femur. Bone tissue
collected from the left fracture site during
surgery showed severe suppression of bone
turnover. Union of bilateral femurs was
achieved after 3 months of a once-weekly
administration of TPTD.
Conclusion: Once-weekly TPTD treatment is
shown to be beneficial for improving the
healing of AFFs showing delayed union.
Keywords: Atypical femoral fractures;
Bisphosphonates; Delayed union; Teriparatide
INTRODUCTION
Atypical subtrochanteric or femoral shaft
fractures occasionally show delayed union,
especially in osteoporosis patients undergoing
long-term treatment with bisphosphonates.
However, there have been few published
studies on the effects of pharmacotherapy on
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these fractures. Previous studies have suggested
that teriparatide (TPTD) therapy can be effective
to promote healing of fractures with delayed
unions [1–6]. However, it is still unknown
whether a once-weekly administration of
TPTD could offer an effective alternative to the
daily TPTD. Herein, the authors report a patient
with delayed union after surgery for an atypical
femoral fracture (AFF) who was effectively
treated with once-weekly administration of
56.5 lg of TPTD.
CASE REPORT
A 74-year-old female patient with osteoporosis,
who had been taking alendronate and
alfacalcidol for approximately 6 years, suffered
femur fractures following a fall in March 2012.
Radiography revealed a subtrochanteric right
femur fracture (Fig. 1a). In addition, her
contralateral thigh showed thickening of the
lateral cortex and a transverse radiolucent
fracture line in the subtrochanter (Fig. 1b). The
patient was diagnosed with AFFs. The patient
had normal levels of bone resorption markers,
but low levels of a bone formation marker
(Table 1).
Four days after admission, the authors
performed minimally invasive osteosynthesis
using intramedullary nails (Fig. 2). Alfacalcidol
was continued but alendronate was ceased. Two
weeks later, low-intensity pulsed
ultrasonography (LIPUS) therapy was started
for both thigh regions to promote bone healing.
In June 2012, radiography and computed
tomography imaging revealed signs of delayed
union at the right fracture site (Fig. 3).
The patient could not walk without a crutch
owing to contralateral thigh pain. After obtaining
informed consent, prophylactic osteosynthesis
was performed on the left subtrochanteric lesion
in June 2012. Bone biopsy samples collected at the
intramedullary nail insertion site revealed an
absence of osteoblasts and osteoclasts on
trabecular surfaces (Fig. 4), as well as low bone
volume (Table 2).
LIPUS treatment was restarted after surgery.
In August 2012, once-weekly TPTD (56.5 lg)
Fig. 1 Radiograph imaging at the time of admission.
a Radiograph imaging at the time of admission shows the
right subtrochanteric fracture with breaking of the lateral
cortex (white arrow) and spiking of the medial cortex (black
arrow). b Zoomed image of the left thigh shows thickening
of the lateral cortex (white arrow) and a transverse
radiolucent fracture line (black arrow)
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was added, and the patient’s tartrate-resistant
acid phosphatase type 5b (TRACP-5b) and
procollagen type 1N-terminal propeptide
(P1NP) levels increased transiently, as did their
lumbar bone mineral density (Table 3). After
3 months of TPTD treatment, the patient’s
fractures had improved (Fig. 5). Administration
of TPTD was terminated in February 2013 and
Table 1 Biochemical markers at the time of admission
Parameters Results Reference
range
Serum calcium (mg/dL) 8.9 8.7–10.3
Serum phosphorous (mg/dL) 2.7 2.5–4.7
Serum alkaline phosphatase (U/L) 163 115–369
Urine NTX (nmol BCE/
mmolCre)
17.1 14.3–89.0
Serum TRACP-5b (mU/dL) 257 120–420
Serum P1NP (lg/L) 6.4 17.0–64.7a
Serum ucOC (ng/mL) 0.39 \4.50
Serum homocysteine (nmol/mL) 8.2 5.1–11.7
Serum pentosidine (pg/mL) 20.3 9.2–43.1
NTX N-telopeptide of type I collagen, P1NP procollagen
type 1N-terminal propeptide, TRACP-5b tartrate-resistant
acid phosphatase type 5b, ucOC uncarboxylated osteocalcin
a Postmenopausal
Fig. 2 Radiograph imaging of the right thigh at the time
of surgery
Fig. 3 Radiograph and CT imaging after 3 months of
LIPUS therapy. a Radiograph imaging after 3 months of
LIPUS therapy shows delayed union at the fracture site.
b CT imaging after 3 months of LIPUS therapy shows
delayed union at the fracture site. CT computerized
tomography, LIPUS low-intensity pulsed ultrasonography
Fig. 4 Trabecular surfaces (9200 magniﬁcation, Villanueva
bone stain) show a total absence of osteoblasts and
osteoclasts (photomicrographs were taken at the Niigata
Bone Science Institute, Niigata, Japan)
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the patient can now walk independently
without crutch.
All procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1975, as revised in
2000 and 2008. Informed consent was
obtained from the patient for being included




























































































































































































































































































































































Table 2 Results of histomorphometric assessment of bone
biopsy specimens
Parameters Abbreviations Results Reference
dataa
Bone volume
Bone volume BV/TV (%) 11.54 11.0 ± 1.8
Trabecular
thickness
Tb.Th (lm) 103.09 131.3 ± 28.1




OV/TV (%) 0.01 0.36 ± 0.31
Osteoid
volume
OV/BV (%) 0.06 1.6 ± 0.4
Osteoid
surface
OS/BS (%) 1.04 12.8 ± 2.2
Osteoid
thickness









Fiber volume Fb.V/TV (%) 0.00 0
NC not calculated
a Reference data from iliac crests of female over 71 years
old
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DISCUSSION
The occurrence of AFFs associated with severely
suppressed bone turnover (SSBT) in
osteoporotic patients receiving
bisphosphonates over prolonged periods was
first reported in 2005 [7]. A task force from the
American Society for Bone and Mineral
Research (ASBMR) defined the major and
minor features of AFFs [8], recommending that
all major features should be present to confirm a
diagnosis of AFF. Bisphosphonates effectively
reduce the risk of femoral neck fractures in
elderly women, but when continued for more
than 5 years, the therapy can result in excessive
suppression of bone turnover, thus increasing
the risk of AFFs [9].
The present case had an approximately
6-year history of alendronate therapy and
subtrochanteric fractures with the major
features designated by ASBMR; therefore, the
case was diagnosed as having bisphosphonate-
associated AFFs. Although urine N-telopeptide
of type I collagen and serum TRACP-5b levels
were normal, the patient’s serum P1NP was low,
suggesting reduced bone formation. Bone
biopsy was performed at the intramedullary
nail insertion site and undecalcified thin
sections were made for trabecular bone
histomorphometry. The data revealed a
decrease in bone formation parameters (wall
thickness, osteoid volume, osteoid surface,
osteoid thickness, osteoblast surface) as well as
a decrease in bone resorption parameters
(eroded surface, osteoclast surface). It was
speculated that the patient’s bone turnover
was extremely low in the proximal femur of
this patient, and that SSBT attributed to
alendronate use for more than 5 years led to
their AFFs and delayed union. On the other
hand, Zanchetta et al. [10] reported that there
were no distinctive microarchitecture features
in the peripheral skeleton of a female patient
who had suffered AFF while receiving
bisphosphonate treatment. So, other factors
including patient characteristics and instability
of osteosynthesis might be concerned with AFFs
and delayed union.
Union of both femur fractures was confirmed
after 3 months of TPTD treatment. It was
Fig. 5 Radiograph and CT imaging after 3 months of
TPTD therapy. a Radiograph imaging after 3 months of
TPTD therapy shows complete union of fractures. b CT
imaging after 3 months of TPTD therapy shows complete
union of the right thigh fracture. c CT imaging after
3 months of TPTD therapy shows complete union of the
left thigh fracture. CT computerized tomography, TPTD
teriparatide
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thought that TPTD stimulated the suppressed
bone formation caused by long-term use of
bisphosphonates. Two types of TPTD injection
are available for treatment of osteoporosis in
patients with a high risk of fracture in Japan:
once-daily 20 lg or once-weekly 56.5 lg. It was
thought that the increased bone formation
owing to TPTD may have accelerated fracture
healing and improved bone union. A search of
the literature revealed several other similar
clinical cases that were successfully treated
with TPTD [1–6]. Aspenberg et al. [11] showed
a shorter healing time in postmenopausal
women with dorsally angulated distal radial
fractures who were treated once daily with
TPTD 20 lg, compared with women treated
with placebo. However, no difference in
fracture healing time was observed between
women treated once daily with TPTD 40 lg and
women treated with placebo [11]. Therefore, it
appears that the dose of TPTD is important to
achieve accelerated fracture repair. Although
the patient in the current study received once-
weekly TPTD, the overall dose received is
considered closer to the once-daily 20 lg dose
than to the once-daily 40 lg dose. Chiang et al.
[12] showed that once-daily TPTD 20 lg
improved the bone quality and healing of
AFFs associated with bisphosphonate therapy,
while Mitani [13] described a case in Japan
showing nonunion of a femoral neck fracture
who, like the patient in the current study,
benefited from once-weekly treatment with
TPTD 56.5 lg. Collectively, these findings [13],
together with the findings in the current case,
suggest that fracture repair might be accelerated
by once-weekly treatment with TPTD 56.5 lg, or
once-daily treatment with TPTD 20 lg. Warden
et al. [14] reported in animal model that TPTD
and LIPUS have contrasting additive effects
during fracture healing, and the patient in the
current case treated with TPTD and LIPUS, so
the fracture repair might be due to the
combination therapy. Based on the authors’
experience, it is suggested that once-weekly
TPTD treatment is beneficial for improving the
healing of AFFs showing delayed union as well
as other fracture treatment methods including
electrical stimulation, bone graft, bone
morphogenetic proteins, and LIPUS.
CONCLUSION
Suppressed bone formation caused by long-term
bisphosphonate therapy can delay the union of
fractures in osteoporotic patients. Although
TPTD administration has been shown to
accelerate the healing in such patients, it is
not clear if daily or weekly treatments are
required. The authors demonstrate in this
report that weekly treatments are sufficient
and should be considered for treating patients
with AFFs with delayed union.
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